Zila Signs Agreement to Expand Distribution of Peridex(R) into Greece.

PHOENIX -- Zila, Inc., (Nasdaq: ZILA) announced that its wholly owned subsidiary, Zila Pharmaceuticals, Inc., manufacturer and marketer of Peridex, has established an exclusive supply agreement with Aven Dental S.A of Athens, Greece for the distribution of Peridex in Greece.

"We are very pleased to have established a presence in Greece and look forward to expanding Peridex throughout the European Union," stated Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila. "We are excited about this opportunity to develop and grow the international business for Peridex and Zila Pharmaceuticals."

About Peridex(R)

Peridex is the leading brand-name prescription mouth rinse for the treatment of gingivitis. Peridex reduces the redness, swelling and bleeding of gums caused by gingivitis. With a pleasant herbal mint taste, Peridex continues to work even after rinsing because one third of its active ingredient -- chlorhexidine gluconate -- binds to oral surfaces and is slowly released to extend its effectiveness for up to 12 hours. Peridex is the first prescription oral rinse to receive the ADA Seal of Acceptance for the treatment of gingivitis. Peridex is endorsed by leading dentists and dispensed by leading pharmacies throughout the United States and Canada.

Visit www.peridex.net for more information about Peridex and Zila Pharmaceuticals.

About Aven Dental S.A.

Aven Dental S.A. was founded in 1979 to provide leading dental products to the Greek market. Aven currently represents many well known companies and brands including OralB/Rembrandt, Parkell, and Orascoptic. In 2000, Aven Dental founded a subsidiary company to represent and market its dental products in Crete. Since 2001, Aven Dental has published the newspaper "Aven Dental Family" with information, techniques and informative articles for the Greek professional dental market.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:

--Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies.

--Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus oral examination kits and Peridex(R) prescription periodontal rinse.

--Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E.

--For more information about Zila, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2005.